Drugs / VMD-928
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03556228 | Jun 2018 → Dec 2027 expected | adenoid cystic carcinoma, esophageal cancer, head and neck squamous cell carcinoma, hypopharynx cancer +10 | VM Oncology, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VMD-928 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03556228 ↗ |
| Route | Oral | “Taken orally once daily for 21 days per 21-day cycle” NCT03556228 ↗ |